Journal of Cardiovascular Development and Disease (Jan 2022)

Eradication of Ventricular Assist Device Driveline Infection in Paediatric Patients with Taurolidine

  • Johannes Weichsel,
  • Benito Baldauf,
  • Hendrik Bonnemeier,
  • Ernest W. Lau,
  • Sven Dittrich,
  • Robert Cesnjevar

DOI
https://doi.org/10.3390/jcdd9010018
Journal volume & issue
Vol. 9, no. 1
p. 18

Abstract

Read online

Ventricular assist devices (VADs) are used to provide mechanical circulatory support to patients with end-stage heart failure. The driveline connecting the external power source to the pump(s) of the intra-corporal VAD breaches the protective skin barrier and provides a track for microbes to invade the interior of the patient’s body. Driveline infection constitutes a major and potentially fatal vulnerability of VAD therapy. Driveline infection cannot traditionally be salvaged and requires the extraction of the entire VAD system. We report here the successful eradication of a VAD driveline infection with a taurolidine-containing antimicrobial solution used for preventing the infection of cardiac implantable electronic devices. If replicated in more cases, the novel treatment concept described here may provide a valuable alternative management strategy of salvage rather than explantation for VAD driveline infection.

Keywords